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Background/aim: There is limited data on COVID-19 disease in children with kidney disease. We aimed to investigate the characteristics
and prognosis of COVID-19 in pediatric nephrology patients in Turkey.
Materials and methods: This was a national, multicenter, retrospective cohort study based on an online survey evaluating the data
between 11th March 2020 and 11th March 2021 as an initial step of a detailed pediatric nephrology COVID-19 registry.
Results: Two hundred and three patients (89 girls and 114 boys) were diagnosed with COVID-19. One-third of these patients (36.9%)
were between 10–15 years old. Half of the patients were on kidney replacement therapy: kidney transplant (KTx) recipients (n = 56,
27.5%), patients receiving chronic hemodialysis (n = 33, 16.3%) and those on peritoneal dialysis (PD) (n = 18, 8.9%). Fifty-four (26.6%)
children were asymptomatic. Eighty-two (40.3%) patients were hospitalized and 23 (28%) needed intensive care unit admission. Fiftyfive percent of the patients were not treated, while the remaining was given favipiravir (20.7%), steroid (16.3%), and hydroxychloroquine
(11.3%). Acute kidney injury developed in 19.5% of hospitalized patients. Five (2.4%) had MIS-C. Eighty-three percent of the patients
were discharged without any apparent sequelae, while 7 (3.4%) died. One hundred and eight health care staff were infected during the
study period.
Conclusion: COVID-19 was most commonly seen in patients who underwent KTx and received HD. The combined immunosuppressive
therapy and frequent exposure to the hospital setting may increase these patients’ susceptibility. Staff infections before vaccination era
were alarming, various precautions should be taken for infection control, particularly optimal vaccination coverage.
Key words: Children, COVID-19, kidney, pediatric nephrology, Turkey

1. Introduction
Coronavirus disease 2019 (COVID-19) is a novel viral
disease caused by the Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) virus, which has been
declared a pandemic due to its global spread [1,2]. One year
after the first confirmed case of COVID-19 in Turkey on
March 11th, 2020, the total number of infected individuals
reached approximately 3 million at the end of the first year
[3]. The epidemiological characteristics of children infected
with SARS-CoV-2 are limited; however, its incidence is
much lower than in adults. Published studies in the early
months of the pandemic suggest that children corresponded
to less than 5% of all COVID-19 cases and they were less
likely to become severely ill compared to adults [4,5].
However, with the spread of new variants, the frequency
of pediatric patients has increased as of May 2021. Despite
excellent overall pediatric outcomes, severe and fatal cases
do occur [6]. Children with severe COVID-19 are more
likely to have preexisting chronic medical conditions (e.g.,
cardiac, respiratory, neurodevelopmental, malignancy, or
immunosuppression) [4,7–10]. However, most children
present clinical symptoms ranging from asymptomatic to
mild/moderate illness and relatively fewer children with
COVID-19 require hospitalization or admission to the
intensive care unit (ICU) [11].
Several reports regarding adults have reported
underlying pathologies or preexisting comorbidities as
important risk factors for severe COVID-19 [12]. Chronic
kidney disease (CKD) was found to be associated with the
severity and mortality of COVID-19 [13,14]. Specifically,
patients with CKD had a three-fold risk of developing
severe COVID-19 [15]. Also, pediatric patients on dialysis

are at significant risk for experiencing infectious diseases
such as COVID-19 because of their compromised immune
system and their frequent exposure to the hospital
setting [16]. About one-third of end-stage kidney disease
(ESKD) patients with dialysis who were hospitalized
with COVID-19 died [17]. The high mortality rate
might be associated with the diminished immune system
from uremia in ESKD patients [18]. However, pediatric
nephrology (PN) patients, i.e. CKD, hemodialysis (HD),
and kidney transplantation (KTx) patients and those on
immunosuppressive treatment were reported to have a
lower risk compared to adults in limited studies [5, 19–
21].
We conducted this multicenter, national collaborative
study to investigate the one-year data of characteristics
and prognosis of COVID-19 in pediatric nephrology
patients in Turkey as an initial step of a detailed pediatric
nephrology COVID-19 registry.
2. Materials and methods
2.1. Study design
This was a nationwide, multi-center, retrospective cohort
study based on the data collected from children and
adolescents with COVID-19 who were followed up in
pediatric nephrology departments between 11th March
2020 (the day of detection of the first case in Turkey) and
11th March 2021. An online questionnaire was sent to all
pediatric nephrology centers in Turkey. The centers were
requested to submit all confirmed cases of COVID-19
(inpatients and outpatients) under the age of 20 years. A
total of 35 pediatric nephrology centers reported their
COVID-19 cases during a study period.
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The online questionnaire forms included information
on demographics, primary renal diagnosis as well as kidney
replacement therapy modality and associated medications,
comorbid conditions such as obesity, hypertension,
cardiovascular diseases or growth retardation and disease
presentation, diagnostic tools for COVID-19, hospital
and/or intensive care unit (ICU) stay, and outcome of the
COVID-19 disease course.
This study was approved by the Ethics and Clinical
Research Committee of Gazi University.
2.2. Diagnostic tools for COVID-19 and definitions
COVID-19 was diagnosed by laboratory confirmation
using the reverse transcriptase-polymerase chain reaction
(PCR) by Bio-Speedy® SARSCoV-2 real time PCR kit or
serology tests. Also, patients with thorax tomography
findings and those having highly suggestive clinical
symptoms compatible with COVID-19 such as fever,
cough, shortness of breath, tiredness, loss of taste and
smell, headache, or myalgia were also diagnosed as
COVID-19 [1]. COVID-19 disease severity, method of
diagnosis, treatment, length of hospital stay, and disease
outcome was documented. The severity of the disease was
classified as mild, moderate, severe, or critical illness. The
mild disease was defined as upper respiratory symptoms
for a short duration or asymptomatic infection; moderate
disease as mild pneumonia symptoms; severe disease as
mild or moderate clinical features, plus any manifestations
that suggest disease progression; critical illness as rapid
disease progression, plus any other conditions like a
respiratory failure with need for mechanical ventilation,
septic shock, organ failure that needs monitoring in the
intensive care unit [22].
Regarding comorbid conditions, obesity was defined as
a body mass index above the 95th percentile according to the
national pediatric growth percentiles [23]. Hypertension
was defined as an office blood pressure greater than the
95th percentile according to age, sex, and height specific
normative values in the Fourth Report [24]. The number
of patients with the multisystem inflammatory syndrome
(MIS-C), characterized by fever, systemic inflammation,
and multiple organ involvement requiring hospitalization
due to confirmed SARS-CoV-2 infection, was also
reported [25]. Acute kidney injury was defined as an
increase of serum creatinine by 0.3 mg/dL or 50% from
baseline within 7 days, according to the Kidney Disease:
Improving Global Outcomes [26].
2.3. Statistical analysis
In the presentation of descriptive statistics, the categorical
data were expressed as numbers (percentages).
3.Results
Data were collected from a total of 35 centers, including
26 (74.3%) university hospitals and 9 (25.7%) Ministry of
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Health Affiliated Hospitals. Twenty-eight (77.1%) centers
have HD, PD, and KTx facilities. Demographic and clinical
characteristics of patients are given in Tables 1 and 2.
Among 203 patients (89 girls and 114 boys) diagnosed
with COVID-19, one-third (36.9%) were between 10–15
years old and almost two-thirds (60.5%) were between 10–
18 years. Only 5.4% of the patients were under 2 years of age
(Table 1). Kidney transplant recipients comprised the main
group (n = 56, 27.5%) and followed by patients receiving
chronic HD (n = 33, 16.3 %), glomerulopathies (n = 31,
15.2%) and those on PD (n = 18, 8.9 %). Half of the patients
with glomerulopathies were on a single or combination of
conventional and/or biologic immunosuppressives. Other
diagnostic groups are listed in Table 1. Almost half (n =
100, 49.3%) of the children had at least one comorbid
condition, and 30% of them had multiple comorbidities.
Fifty-six percent of the patients were diagnosed when
they applied to the hospital with complaints, either in the
same clinic (n = 56, 42.3%) or in another health center (n
= 28, 13.7%). Other patients had their diagnosis during
PCR screening tests; 62 (30.5%) patients with a history of
household contact with an index case were diagnosed via
filiation, 18 (8.8%) patients with a routine PCR test before
hospitalization for another reason. One hundred and
seventy (83.7%) patients were diagnosed as COVID-19
disease by SARS-CoV-2 PCR test positivity, 12 (5.9%) by
SARS-CoV-2 immunoglobulin M positivity, 11 (5.4%) by
thorax tomography findings compatible with COVID-19
pneumonia and 10 (4.9%) by highly suggestive clinic
symptoms like fever, cough or shortness of breath that
were not explained by another cause.
Fifty-four (26.6%) children were asymptomatic, and
67 (33%) children presented with mild symptoms. Eightytwo (40.3%) patients were hospitalized and 23 (28%) of
them needed ICU stay. The patients were most frequently
hospitalized for 3–7 days (35.4%) and 7–14 days (31.7%).
Only seven (8.5%) patients required >30 days of hospital
stay. More than half of the patients (55%) were not treated,
while the remaining patients were mostly given favipiravir
(20.7%), steroids (16.3%), and hydroxychloroquine
(11.3%). Some of the patients were treated with additional
combination regimens of intravenous immunoglobulin
(IVIG), low molecular weight heparin (LMWH), or
biologic anticytokine therapies. Acute kidney injury
developed in 19.5% of the hospitalized patients during
the course of the disease. Five patients (2.4%) had the
diagnosis of MIS-C. A total of 7 (3.4%) patients died during
the study period. Of the patients who died, 3 (42.8%) died
due to MIS-C, 2 (28.5%) due to COVID-19 pneumonia, 1
(14.2%) due to post-COVID cardiac arrest after discharge
from the hospital, and 1 (14.2%) due to COVID-unrelated
reason. Fortunately, 83% of the patients were discharged
without any apparent sequelae.
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Table 1. Demographic characteristics of patients with COVID-19.
All patients with COVID-19, n (%)

Age (years), n (%)

Gender, n (%)

Patient groups according to renal replacement therapy or
primary diagnostic category, n (%)

Comorbidities, n (%)

203 (100)
0–1

5 (2.4)

>1–2

6 (2.9)

>2–5

18 (8.8)

>5–10

38 (18.7)

>10–15

75 (36.9)

>15–18

48 (23.6)

>18

13 (6.4)

Female

89 (43.8)

Renal transplantation

56 (27.5)

Hemodialysis

33 (16.2)

Peritoneal dialysis

18 (8.8)

ESKD

20 (9.8)

Glomerulopathy

31 (15.2)

Hypertension

10 (4.9)

CAKUT

13 (6.4)

Tubular diseases

8 (3.9)

Cystic kidney diseases

4 (1.9)

Other

10 (4.9)

Any comorbid condition

100 (49.3)

Single comorbidity

70 (34.5)

Multiple comorbidity

30 (14.8)

Obesity

15 (7.4)

COVID-19: Coronovirus-19 disease; ESKD: End-stage kidney disease; CAKUT: Congenital anomalies of the kidney and urinary tract

In addition, a total of 108 healthcare staff members,
25 of whom were pediatric nephrologists and 27 of whom
were nurses, were infected. Vaccination was available for
healthcare staff in the second half of January 2021 and staff
infections were all recorded prior to the vaccination era.
4. Discussion
In this one-year retrospective study, starting from the
day of the first COVID-19 case detected in Turkey, the
characteristics of 203 pediatric nephrology patients
diagnosed with COVID-19 were evaluated. More than half
of the patients were asymptomatic or mildly symptomatic.
Although the hospitalization rate in PN patients was 40.3%,
most of the patients were discharged without any sequelae.
However, viral transmission to healthcare personnel in
prevaccination era was remarkable.
COVID-19 disease is not only a respiratory infection
but also a systemic disease that affects multiple organs. Since
the SARS CoV-2 virus uses the angiotensin-converting
enzyme-2 (ACE2) and transmembrane protease serine

type 2 receptors to enter the cell and these molecules are
highly expressed in kidney cells, the kidneys are one of the
organs most frequently affected by COVID-19 disease. It
causes directly parenchymal infection in tubule epithelial
cells and podocytes, acute tubular injury, and acute tubular
necrosis. The most common signs of renal involvement
are increased serum creatinine level, proteinuria, and
hematuria. Patients with preexisting kidney disease are at
higher risk of developing serious illnesses from COVID-19
[27]. Therefore, it is essential to prevent kidney damage
due to COVID-19 and to protect patients with kidney
disease from the increased morbidity and mortality risks
of COVID-19.
A study evaluating previously healthy patients in the
0–15 age group observed that 18.1% of patients were <1
year of age, 23.4% were 1–5 years, 33.9% were 6–10 years,
24.6% were 11–15 years [1]. In our study, when patients in
the 0–15 age range with a known kidney pathology were
evaluated, only 3.5% of patients were <1 year of age, 16.9%
were 1–5 years, 26.7% were 6–10 years, 52.8% were 11–15
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Table 2. Clinical characteristics of patients with COVID-19.
All patients with COVID-19, n (%)
Outpatient clinic, n (%)
Hospitalized patients, n (%)

How to reach a diagnosis, n (%)

Primary method for diagnosing COVID-19, n (%)

Treatments, n (%)

Length of hospital stay, n (%)
(n = 82)

Outcomes, n (%)

203 (100)
Asymptomatic
Mild symptomatic
Moderate
Severe/critical
Filiation
Admitting to hospital with complaints
Routine PCR test prior to hospitalization for another reason
Diagnosis at another center
During a regular visit, screening tests due to family history
SARS CoV-2 PCR test
SARS CoV-2 IgM-IgG
Thorax computer tomography
High clinical suspicion
No treatment
Favipiravir
Oseltamivir
Lopinavir-ritonavir
Remdesivir
Antibiotics
Hydroxychloroquine
Steroids
Anakinra
LMWH
Aspirin
IVIG
Plasmaexchange
1–3 days
3–7 days
7–14 days
14–21 days
21–30 days
30 days
Acute kidney injury
Patients discharged from ward with no sequelae
Patients discharged from ward with sequelae
Patients currently hospitalized in ward
Patients discharged from ICU with no sequelae
Patients discharged from ICU with sequelae
Patients currently in ICU
New oncet MIS-C and Kawasaki-like MIS-C
Exitus

54 (26.6)
67 (33)
59 (29)
23 (11.3)
62 (30.5)
86 (42.3)
18 (8.8)
28 (13.7)
9 (4.4)
170 (83.7)
12 (5.9)
11 (5.4)
10 (4.9)
112 (55)
42 (20.7)
5 (2.5)
5 (2.5)
1 (0.5)
18 (8.9)
23 (11.3)
33 (16.3)
6 (3)
8 (3.9)
5 (2.5)
13 (6.4)
2 (1)
2 (2.4)
29 (35.4)
26 (31.7)
14 (17)
4 (4.8)
7 (8.5)
16 (7.8)
56 (27.6)
1 (0.5)
2 (1)
12 (5.9)
3 (1.5)
1 (0.5)
5 (2.5)
7 (3.4)

COVID-19: Coronavirus-19 disease; PCR: Polymerase chain reaction; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus
2; IgM: Immunoglobulin M; IgG: Immunoglobulin G; LMWH: Low molecular weight heparin; IVIG: Intravenous immunoglobulin;
ICU: Intensive care unit; MIS-C: Multisystem inflammatory syndrome-children
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years. The reason why the frequency of COVID-19 in the
first year of life was less compared to the literature is that
our cases have various renal diseases, and the frequency of
these pathologies increases with age.
In a study in which pediatric patients followed up
with the diagnosis of inflammatory rheumatoid disease
were compared with a healthy control group, it was
shown that the presence of inflammatory rheumatoid
disease increased the risk of symptomatic infection and
hospitalization in terms of COVID-19 disease. It was also
shown in that study that the risk of symptomatic infection
increases with age [28]. In terms of kidney diseases, CKD
was reported to be associated with increased risk, severity,
and mortality of COVID-19 disease in adults, however,
there is limited information on PN patients [15–17].
In a pediatric study from Spain, 18.7% of patients with
COVID-19 had a KTx, and 18.7% were receiving chronic
HD [29]. According to our data, 27.5% of the infected
patients were KTx recipients, 16.3% were undergoing
HD, 8.9% were on PD, 15.2% had glomerulopathies and
9.8% had nondialysis dependent CKD (stage I-V). The
higher rates in PN patient groups may be due to their
compromised immune system and their more frequent
exposure to the hospital setting, i.e. in center HD patients.
There is limited evidence in children with KTx suggesting
not an increased risk of severe COVID-19 disease
[30–33]. Evidence from similar adult KTx populations
suggests an increased risk of acquiring COVID-19 and an
increased risk of severe disease [34–39]. The incidence of
COVID-19 was reported to be similar between pediatric
KTx recipients and the general pediatric population [30].
In a study from Turkey evaluating 496 pediatric dialysis
and KTx patients, the diagnosis of COVID-19 was made in
46 (9.2%) patients; among them, 63% were KTx recipients
and 37% were on dialysis. Although the patients were
usually asymptomatic or mildly symptomatic, 22 (47.8%)
patients were hospitalized. One patient who underwent
HD and had serious comorbid diseases died. The mortality
rate was 2% in SARS-CoV-2 positive patients and 4.5%
among hospitalized ones [40]. In our study, 82 (40.3%)
patients were hospitalized for COVID-19. Twenty-three
(11.3%) patients were followed up in the ICU. A total of
7 patients died, including 3 patients with MIS-C, 2 with
COVID-19 pneumonia, 1 with sudden cardiac arrest at
home after discharge, and 1 with COVID-19-unrelated
reasons. We observed the hospitalization rate as 40.3% and
the mortality rate as 3.4%. These rates are broadly similar
in both studies.
In a study from Turkey including 76 pediatric patients
without kidney disease who developed MIS-C, 35.5% of
the patients were followed in the ICU and one patient
died [41]. In another study conducted on 113 children
with kidney disease, no MIS-C cases were reported [42].

Similarly, among pediatric dialysis and KTx patients,
only two (0.4%) MIS-C cases were detected without any
mortality [40]. Discrepant results in small studies may be
due to baseline characteristics and comorbid conditions of
the patients and highlighted the necessity of large studies
to evaluate the role of underlying kidney disease as risk
factors for MIS-C.
Unlike adults, most children present clinical symptoms
ranging from asymptomatic to mild/moderate illness
[5,43–46]. According to our observation, 26.6% of
cases were asymptomatic and 33% cases were mildly
symptomatic. Similarly, in another study evaluating
children with chronic renal pathologies, 18.7% of patients
were asymptomatic, and there were fever and/or cough
as the symptoms in 50% of patients [29]. This may be
related to the differences in pediatric innate immune
system compared to adults, being familiar with other
coronaviruses, having fewer ACE2 receptors in the nasal
mucosa, or having fewer comorbidities such as diabetes
and hypertension [44].
Acute kidney injury (AKI) is commonly seen during
COVID-19 course, especially in patients with KTx
[15,16,45]. Several systematic reviews reported the
association of AKI in severe COVID-19 patients with
a poorer prognosis. During COVID-19 course, 27% to
52% of adult KTx recipients and 36% of pediatric KTx
recipients developed AKI [47–50]. In our study, 19.5%
of hospitalized patients developed AKI. The lower rate of
AKI in our study may be explained by recruited patient
population which included not only transplant or stage
3–5 CKD patients, but also other kidney pathologies with
normal basal kidney functions.
There is currently limited evidence to support the
efficacy of a specific antiviral and/or immunomodulatory
agent for the treatment of COVID-19 in adults, and no
evidence in children [51–55]. In Turkey, antiviral therapy
has been prescribed according to guidelines published by
the Turkish Ministry of Health [56]. In the first months
of the pandemic, hydroxychloroquine was used in the
treatment of COVID-19 because it was observed that the
risk of ICU admissions was decreased with the use of it [57].
However, since it was seen that it did not reduce the risk of
hospitalization or mortality rates in later studies, its use in
treatment was terminated [58]. In this study, we observed
that treatment regimens were highly heterogeneous.
Asymptomatic or mildly symptomatic patients were not
treated while the remaining patients were mostly given
favipiravir and steroids. Some of the patients were treated
with additional combination regimens of IVIG, LMWH,
or biologic anticytokine therapies. When our special
patient group is taken into consideration, it should be kept
in mind that drug interactions may occur due to the usage
of multiple drugs, and the drug doses should be adjusted
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based on renal function. Additionally, there are no general
rules about the management of immunosuppression.
Despite an earlier hesitation on continuation/dose
reduction of immunosuppression, studies in PN patients
suggested that it should be maintained but maybe
individually tailored based on disease severity, which was
confirmed by an adult expert opinion in KTx [24,59]. In
some studies, antimetabolites were typically reduced or
discontinued, but calcineurin inhibitors were maintained
if the clinic was not severe [24].
We observed that there were 108 infected healthcare
staff, accounting for more than half of the COVID-19
positive patients. In a previous study, 204 (4.3%)
healthcare staff were found to be positive for COVID-19
among a total of 4073 hospital staff. Attention was drawn
to the importance of strict infection control measures
to reduce viral transmission, as healthcare workers
are at high risk for COVID-19 [60]. However, all these
infections were recorded before the vaccination era in

health care providers. The optimization of vaccination
coverage should be highlighted to prevent subsequent
infections.
In conclusion, among PN patients, COVID-19 was
most commonly seen in patients who underwent KTx
and undergoing HD. The combined immunosuppressive
therapy and frequent exposure to the hospital setting
may increase these patients’ susceptibility. In the study
presenting data for the prevaccination period, a mortality
rate of 3.4% and staff infections deserve more attention and
further strict precautions. We acknowledge that the data
on COVID-19 are rapidly evolving, and further studies are
needed in pediatric kidney patients.
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